Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors

Ammar Sukari; Misako Nagasaka; Nadine Abdallah

doi:10.1016/j.oraloncology.2018.03.011

Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors

Oral Oncol. 2018 May:80:100-102. doi: 10.1016/j.oraloncology.2018.03.011. Epub 2018 Mar 28.

Authors

Ammar Sukari¹, Misako Nagasaka², Nadine Abdallah³

Affiliations

¹ Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: sukaria@karmanos.org.
² Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Department of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa, Japan.
³ Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA.

PMID: 29605290
DOI: 10.1016/j.oraloncology.2018.03.011

Abstract

This report describes highlights the dramatic responses seen in patients who were given paclitaxel post progression on immunotherapy. There are multiple mechanisms by which synergistic effects of immunotherapy and chemotherapy occur. Further prospective studies on chemotherapy and immunotherapy are eagerly awaited.

Keywords: Chemoimmunotherapy; Head and neck squamous cell carcinoma; Pembrolizumab; Synergy; Taxanes.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Head and Neck Neoplasms / drug therapy*
Humans
Male
Middle Aged
Paclitaxel / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Squamous Cell Carcinoma of Head and Neck / drug therapy*

Substances

PDCD1 protein, human
Programmed Cell Death 1 Receptor
Paclitaxel